Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company founded in 1987 by Brook Byers. It is headquartered in San Diego, California. Ligand specializes in developing and acquiring technologies that aid in the discovery and development of pharmaceutical products. The company is known for its platform technologies, such as Captisol, OmniAb, and Pelican Expression Technology, which are used to facilitate drug discovery and development. Ligand operates through a business model that focuses on alliances and partnerships with other biotech and pharmaceutical companies, providing them with technology and financial flexibility while earning revenue from royalties, milestones, and licensing agreements. The company's business strategy allows it to maintain a broad portfolio of patents and technologies without bearing the full costs of drug development and marketing. Ligand's revenue stems from these strategic collaborations and their successful development by partners. The company is publicly traded on the NASDAQ under the ticker symbol "LGND" and has established itself as a unique player within the biotech industry by fostering an environment of innovation and collaboration.